The $8.30 figure is not an official published consensus; it is an average calculated from nine individual analyst price targets that are attributable to named firms. The range runs from $5.00 at the low end to $13.00 at the high end, and the unrounded mean is approximately $8.33. That wide dispersion is itself informative: analysts agree the shares are undervalued on a directional basis, but disagree sharply on how much upside is justified.
At the cautious end, RBC Capital carries a Hold with a $5 target, and Truist Financial (Gregory Renza) maintained a Buy but trimmed its target to $5 in early October 2026. In the middle, Mizuho and Raymond James both hold $7 targets, while Wedbush's Yun Zhong reiterated a Buy with an $8 target. Cantor Fitzgerald raised its target to $10 from $8, H.C. Wainwright reiterated at $10, and Chardan Capital initiated coverage with a $10 target in October 2026. Wells Fargo remains the most bullish at $13, an Overweight rating it has kept even after prior reductions. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Bullish arguments center on Tyvaso DPI royalty durability and new product launches, while cautious views reflect the company's third-quarter revenue shortfall and the loss of pipeline optionality after the Phase 3 ICoN-1 trial for MNKD-101 was discontinued following a futility assessment. The average should be read as a statistical midpoint across differing opinions, not a guarantee.
MannKind Corporation (MNKD) shares have traded in a volatile range in late 2026, recently around $4.07 after slipping from levels near $4.13 earlier in November. The stock is well below its 52-week high near $6.51 and above its 52-week low near $2.23. At approximately $4.07, the $8.30 target implies upside of about 104%, which is a very large required move by any standard measure.
Fundamentals are improving unevenly. Third-quarter 2026 revenue rose roughly 24% year over year to about $101.9 million, yet that figure came in below consensus estimates near $107.7 million. The company posted an EPS of about -$0.01, better than the roughly -$0.06 to -$0.07 analysts had expected, but MannKind continues to report GAAP losses. Management has highlighted a settlement with Liquidia and United Therapeutics as supportive of near-term Tyvaso DPI royalty durability, and pointed to accelerating pediatric Afrezza adoption as well as the early launch of ReadyFlow, the furosemide delivery device, alongside the Furoscix franchise. A path toward $8.30 would likely require sustained revenue growth, expanding profitability, and successful execution across these launches — a multi-quarter journey, not a single-catalyst event.
The shares are trading in the lower half of a 52-week range of roughly $2.23 to $6.51. Near-term support sits in the $3.85–$4.00 zone, where the stock has repeatedly found buying interest, while the $5.00–$5.50 area has acted as resistance on prior advances. The psychological $5 level, which also coincides with the lowest analyst target, is a meaningful first hurdle. Beyond that, the $6.50 prior high represents a longer-term ceiling that would likely need to be cleared before the $8.30 objective becomes realistic.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts set different assumptions. Investors should watch quarterly revenue versus estimates, EPS progression, pediatric Afrezza prescription trends, ReadyFlow and Furoscix launch metrics, Tyvaso DPI royalty updates, and any new pipeline or business-development announcements. Analyst target revisions — which have moved both up and down in 2026 — will also signal shifting conviction.
Tickeron's AI Daily Buy/Sell Signals help me monitor market conditions and technical behavior across thousands of stocks without constant manual checks. For a name like MannKind Corporation (MNKD) with upcoming commercial catalysts, these signals provide an efficient way to track shifts in momentum alongside my fundamental analysis. I find this approach useful for staying disciplined when volatility is high.
The $8.30 central target, derived as the average of nine analyst price targets spanning $5.00 to $13.00, sits roughly 104% above the recent price near $4.07. Reaching it would require a very large repricing driven by sustained revenue growth, expanding profitability, and successful commercial execution across Tyvaso DPI royalties, pediatric Afrezza, and the Furoscix/ReadyFlow franchise. The main obstacles are the recent revenue miss, persistent GAAP losses, and the loss of MNKD-101 pipeline optionality. The unusually wide analyst range underscores genuine disagreement about how much of that potential is real. The target is an analytical reference point, not a forecast or a recommendation, and investors should weigh the supporting catalysts against the execution risks before forming their own view.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
MNKD saw its Momentum Indicator move below the 0 level on November 20, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 74 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 80%.
The 10-day RSI Indicator for MNKD moved out of overbought territory on November 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 16 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 58 cases where MNKD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for MNKD turned negative on November 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 38 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNKD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
MNKD broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
MNKD moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MNKD crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +8.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where MNKD advanced for three days, in 203 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 143 of 190 cases where MNKD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-18.662) is normal, around the industry mean (3.596). P/E Ratio (-26.000) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (2.832) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. MNKD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNKD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of therapeutic products
Industry Biotechnology